President Donald Trump’s administration is slated to lay out its approach to Covid vaccination at an event Tuesday that could ...

The vaccine, Nuvaxovid, is the third coronavirus shot to gain full approval, joining vaccines from Pfizer and Moderna. It has ...

The U.S. Food and Drug Administration (FDA) has granted full approval to Novavax's COVID-19 vaccine, but only for certain ...

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

The FDA has approved Novavax’s COVID-19 vaccine, Nuvavoxid, for use in adults 65 and older and in individuals ages 12-64 who have at least one underlying health condition. The approval is based on ...

Late-stage trial data suggest that a new COVID-flu vaccine offers good protection against both infections, but experts expect ...

The FDA also requested Novavax conduct a phase 4 study in patients aged 50 to 64 years without high-risk conditions for severe COVID-19.

Novavax had expected full approval for broader use by April 1, after the FDA reviewed data from a 30,000-person clinical ...

In a world of increasing fragmentation and polarisation, the 78th World Health Assembly, starting Monday, will present itself ...